Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Crinetics Pharmaceuticals, Inc. (CRNX : NSDQ)

• Company Description    CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO. Number of Employees: 594

• Price / Volume Information    Yesterday's Closing Price: $36.80 Daily Weekly Monthly 20 Day Moving Average: 1,415,357 shares Shares Outstanding: 105.44 (millions) Market Capitalization: $3,880.19 (millions) Beta: 0.28 52 Week High: $57.99 52 Week Low: $25.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.44% -9.11% 12 Week -15.87% -22.22% Year To Date -20.94% -26.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6055 Lusk Boulevard - San Diego,CA 92121 USA ph: 858-450-6464 fax: - ir@crinetics.com http://www.crinetics.com

• General Corporate Information    Officers R. Scott Struthers - President and Chief Executive Officer Wendell Wierenga - Chairman Tobin Schilke - Chief Financial Officer Camille Bedrosian - Director Caren Deardorf - Director Peer Information Crinetics Pharmaceuticals, Inc. (GSAC) Crinetics Pharmaceuticals, Inc. (CASIF) Crinetics Pharmaceuticals, Inc. (ALCD.) Crinetics Pharmaceuticals, Inc. (OMNN) Crinetics Pharmaceuticals, Inc. (CGPI.) Crinetics Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 22663K107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 105.44 Most Recent Split Date: (:1) Beta: 0.28 Market Capitalization: $3,880.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.03 Price/Cash Flow: - Price / Sales: 214.74 EPS Growth vs. Year Ago Period: -18.27% vs. Previous Quarter: 4.65% Sales Growth vs. Year Ago Period: 2,873.41% vs. Previous Quarter: 74.22% ROE 03/31/26 - -43.96 12/31/25 - -41.46 09/30/25 - -35.09 ROA 03/31/26 - -39.61 12/31/25 - -37.43 09/30/25 - -32.04 Current Ratio 03/31/26 - 18.60 12/31/25 - 12.32 09/30/25 - 15.12 Quick Ratio 03/31/26 - 18.56 12/31/25 - 12.30 09/30/25 - 15.12 Operating Margin 03/31/26 - -2,747.18 12/31/25 - -6,046.22 09/30/25 - - Net Margin 03/31/26 - -2,747.18 12/31/25 - -6,046.22 09/30/25 - - Pre-Tax Margin 03/31/26 - -2,746.18 12/31/25 - -6,043.88 09/30/25 - -27,563.32 Book Value 03/31/26 - 12.15 12/31/25 - 9.71 09/30/25 - 11.30 Inventory Turnover 03/31/26 - 1.00 12/31/25 - 2.13 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©